Humira Will Be Removed from Select Formularies--Effective April 1, 2024
Effective April 1, 2024, Humira will be removed from F2, F3 and FEHBP (F2 CHART and F4 CHART) formularies. Humira will continue to be covered on the Exchange Formulary, F1 and F3 Choice formularies. Biosimilars, including Hyrimoz (adalimumab-adaz), will continue to be available across all formularies.
To learn more, please review this Provider News in its entirety.